Read + Share
Amedeo Smart
Independent Medical Education
Mealli F, Mattei A, Mariottini A, Massacesi L, et al. Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study. Mult Scler 2024;30:1077-1080.PMID: 38481074
Email
LinkedIn
Privacy Policy